Drugs for Spontaneous Ocular Nystagmus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 22)
| # |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
| 1 |
|
Dopamine |
Approved |
Phase 4 |
|
51-61-6, 62-31-7 |
681 |
|
Synonyms:
(3H)-Dopamine
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-dihydroxyphenyl)ethylamine
2-(3,4-Dihydroxyphenyl)ethylamine
2-benzenediol
3,4 Dihydroxyphenethylamine
3,4-dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-aminoethyl)catechol
4-(2-Aminoethyl)catechol
4-(2-aminoethyl)pyrocatechol
4-(2-aminoethyl)-pyrocatechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)-pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
a-(3,4-Dihydroxyphenyl)-b-aminoethane
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
ASL 279
BIDD:ER0506
Biomol-NT_000001
BPBio1_001123
BSPBio_001932
C03758
CHEBI:18243
CHEMBL59
CID681
cMAP_000036
cMAP_000065
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
dopamine
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine [INN:BAN]
Dopamine hydrochloride
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydrochloride, dopamine
|
Hydroxytyramin
hydroxytyramine
Hydroxytyramine
IDI1_000780
intropin
Intropin
Intropin [*hydrochloride*]
IP 498
KBio1_000780
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L000232
L-DOPAMINE
LDP
Lopac0_000586
Lopac-H-8502
LS-159
Medopa (TN)
m-Hydroxytyramine hydrochloride
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
Spectrum_001012
SPECTRUM1505155
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
ST048774
STK301601
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
|
|
| 2 |
|
Memantine |
Approved, Investigational |
Phase 4 |
|
19982-08-2 |
4054 |
|
Synonyms:
1,3-Dimethyl-5-adamantanamine
1,3-Dimethyl-5-aminoadamantane
19982-08-2
1-amino-3,5-Dimethyladamantane
1-Amino-3,5-dimethyladamantane
3,5-Dimethyl-1-adamantanamine
3,5-Dimethyl-1-adamantylamine
3,5-Dimethyl-1-aminoadamantane
3,5-dimethyladamantan-1-amine
3,5-Dimethyladamantan-1-ylamine
3,5-dimethyltricyclo(3.3.1.1(3,7))Decan-1-amine
3,5-Dimethyltricyclo(3.3.1.1(3,7))decan-1-amine
3,5-dimethyltricyclo[3.3.1.1~3,7~]decan-1-amine
41100-52-1 (Hydrochloride)
51052-62-1
AB00053600
AC1L1HB7
AKOS000113995
Axura
BBL000737
Biomol-NT_000209
BPBio1_001117
BPBio1_001270
BSPBio_001015
C13736
CBMicro_020348
CHEBI:152523
CHEMBL807
CID4054
D08174
DB01043
DivK1c_000068
DMAA
Ebixa
EU-0053634
Exiba
Exiba (TN)
HMS500D10
HSDB 7327
IDI1_000068
KBio1_000068
KBio2_001087
KBio2_003655
|
KBio2_006223
KBio3_001926
KBioGR_001543
KBioSS_001087
Lopac0_000861
LS-157051
Lundbeck brand OF memantine hydrochloride
Memantin
Memantina
Memantina [INN-Spanish]
memantine
Memantine
Memantine (INN)
Memantine [INN:BAN]
Memantine [INN]
Memantine HCL
Memantine hydrochloride
Memantine Hydrochloride
Memantinum
Memantinum [INN-Latin]
Merz brand OF memantine hydrochloride
MolPort-002-041-858
Namenda
NCGC00015705-05
NCGC00024782-02
NCGC00024782-03
NINDS_000068
Oprea1_480562
Prestwick0_000978
Prestwick1_000978
Prestwick2_000978
Prestwick3_000978
SPBio_001456
SPBio_002926
Spectrum_000607
Spectrum2_001408
Spectrum3_000923
Spectrum4_001022
Spectrum5_001355
ST057652
STK520682
UNII-W8O17SJF3T
ZERO/006024
|
|
| 3 |
|
Gabapentin |
Approved, Investigational |
Phase 4 |
|
60142-96-3 |
3446 |
|
Synonyms:
[1-(AMINOMETHYL)CYCLOHEXYL]ACETIC ACID
1-(Aminomethyl)cyclohexaneacetate
1-(Aminomethyl)cyclohexaneacetic acid
1-(Aminomethyl)-cyclohexaneacetic acid
2-[1-(aminomethyl)cyclohexyl]acetic acid
60142-96-3
AC-1485
AC1L1FYE
AC1Q53PH
Aclonium
AKOS000280865
apo-Gabapentin
Apo-Gabapentin
Apotex brand of gabapentin
Aventis brand of gabapentin
BB_SC-1512
BIDD:GT0656
BPBio1_000993
BRN 2359739
BSPBio_000901
C040029
C9H17NO2
CAS-60142-96-3
CCRIS 7210
CHEBI:188316
CHEBI:42797
CHEMBL940
CI 945
CI-945
CID3446
Convalis
D00332
DB00996
DDS-2003
DM-1796
DM-5689
EINECS 262-076-3
EU-0100582
G0318
G-154
G154_SIGMA
Gabapen
gabapentin
Gabapentin
Gabapentin (JAN/USAN/INN)
gabapentin (Neurontin)
Gabapentin [USAN:INN:BAN]
Gabapentin GR
Gabapentin hexal
Gabapentin Hexal
Gabapentin stada
Gabapentin Stada
gabapentina
Gabapentina
Gabapentine
Gabapentine [INN-French]
gabapentinium
Gabapentino
|
Gabapentino [INN-Spanish]
Gabapentino [Spanish]
Gabapentin-ratiopharm
Gabapentinum
Gabapentinum [INN-Latin]
Gabapetin
GBN
Go 3450
GOE 2450
Goe-3450
Hexal brand of gabapentin
HMS1570N03
HMS2089J03
HSDB 7364
I06-0677
L000733
Lopac0_000582
Lopac-G-154
LS-7194
MLS000069358
MolPort-000-883-862
NCGC00015466-01
NCGC00015466-02
NCGC00015466-06
NCGC00015466-09
NCGC00016891-01
NCGC00021545-02
NCGC00021545-04
NCGC00021545-05
Neurontin
Neurontin (TN)
novo-Gabapentin
Novo-Gabapentin
novo-Gabapentine
Novopharm brand of gabapentin
NSC742194
Parke Davis brand of gabapentin
Pfizer brand of gabapentin
Pharmascience brand of gabapentin
PMS-Gabapentin
Prestwick_151
Prestwick0_000861
Prestwick1_000861
Prestwick2_000861
Prestwick3_000861
ratiopharm brand of gabapentin
S2133_Selleck
Serada
SMR000058311
SPBio_002822
Stadapharm brand of gabapentin
STK598009
TL8003814
Tocris-0806
UNII-6CW7F3G59X
Vultin
Warner-Lambert brand of gabapentin
|
|
| 4 |
|
Brinzolamide |
Approved |
Phase 4 |
|
138890-62-7 |
68844 |
|
Synonyms:
(+)-4-ETHYLAMINO-3,4-DIHYDRO-2-(METHOXY)PROPYL-2H-THIENO[3,2-E]-1,2-THIAZINE-6-SULFONAMIDE-1,1-DIOXIDE
(4R)-4-(ethylamino)-2-(3-methoxypropyl)-1,1-dioxo-3,4-dihydrothieno[3,2-e]thiazine-6-sulfonamide
(4R)-4-(ethylamino)-2-(3-methoxypropyl)-3,4-dihydro-2H-thieno[3,2-e][1,2]thiazine-6-sulfonamide 1,1-dioxide
(R)-4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2H-thieno(3,2-e)-1,2-thiazine-6-sulfonamide
(R)-4-(Ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2H-thieno(3,2-e)-1,2-thiazine-6-sulfonamide 1,1-dioxide
138890-62-7
2H-Thieno(3,2-e)-1,2-thiazine-6-sulfonamide,4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-,1,1-dioxide,R
3znc
AB00513824
AC1L2AKA
AC1Q6UVB
AC-5277
AKOS005145708
AL 4862
AL04862
AL-4862
Alcon brand of brinzolamide
Alcon brand OF brinzolamide
Allphar brand of brinzolamide
Allphar brand OF brinzolamide
Azopt
Azopt (TN)
BIDD:GT0039
Birnzolamide
BPBio1_000539
BRD-K74913225-001-03-3
Brinzolamida
|
Brinzolamide
Brinzolamide (BRZ)
Brinzolamide (JAN/USP/INN)
Brinzolamide [USAN]
BSPBio_000489
BZ1
C07760
C111827
C12H21N3O5S3
CHEBI:3176
CHEMBL220491
CID68844
D00652
DB01194
FT-0082471
HMS1569I11
I09-0605
LS-173036
MLS002153787
MolPort-005-940-291
Prestwick0_000365
Prestwick1_000365
Prestwick2_000365
Prestwick3_000365
SMR001233169
SPBio_002410
UNII-9451Z89515
|
|
| 5 |
|
Anti-Anxiety Agents |
|
Phase 4 |
|
|
|
| 6 |
|
Analgesics |
|
Phase 4 |
|
|
|
| 7 |
|
Neurotransmitter Agents |
|
Phase 4 |
|
|
|
| 8 |
|
Tranquilizing Agents |
|
Phase 4 |
|
|
|
| 9 |
|
Dopamine Agents |
|
Phase 4 |
|
|
|
| 10 |
|
Psychotropic Drugs |
|
Phase 4 |
|
|
|
| 11 |
|
Anticonvulsants |
|
Phase 4 |
|
|
|
| 12 |
|
Antiparkinson Agents |
|
Phase 4 |
|
|
|
| 13 |
|
Antimanic Agents |
|
Phase 4 |
|
|
|
| 14 |
|
Central Nervous System Depressants |
|
Phase 4 |
|
|
|
| 15 |
|
Excitatory Amino Acid Antagonists |
|
Phase 4 |
|
|
|
| 16 |
|
Excitatory Amino Acids |
|
Phase 4 |
|
|
|
| 17 |
|
Pharmaceutical Solutions |
|
Phase 4 |
|
|
|
| 18 |
|
Ophthalmic Solutions |
|
Phase 4 |
|
|
|
| 19 |
|
Carbonic Anhydrase Inhibitors |
|
Phase 4 |
|
|
|
| 20 |
|
4-Aminopyridine |
Approved |
Phase 1, Phase 2 |
|
504-24-5 |
1727 |
|
Synonyms:
.gamma.-Aminopyridine
[J.Pharmacol.Exp.Ther. 275:864 (1995)]
275875_ALDRICH
36687_FLUKA
36687_RIEDEL
4 Aminopyridine
4 Aminopyridine Sustained Release
4 AP
4-aminopyridine
4-Aminopyridine
4-Aminopyridine 10
4-Aminopyridine Sustained Release
4-AP
4-Pyridinamine
4-Pyridylamine
504-24-5
5-22-09-00106 (Beilstein Handbook Reference)
A 0152
A0414
A78403_ALDRICH
AB1004971
AC1L1C3R
AC1Q52BM
AC-907/25014071
AI3-52547
AKOS000119896
Amaya
Amino-4 pyridine
Amino-4-Pyridine
Ampydin
Ampyra
Avitrol
Avitrol 200
BB_SC-6974
Bio1_000353
Bio1_000842
Bio1_001331
Bio2_000282
Bio2_000762
BRN 0105782
BSPBio_001562
C13728
C5H6N2
Caswell No. 038
CHEBI:34385
CHEMBL284348
CID1727
Compound 1861
D015761
D04127
Dalfampridine
DivK1c_000572
EINECS 207-987-9
EL-970
EPA Pesticide Chemical Code 069201
EU-0100032
Fampridina
Fampridine
Fampridine (USAN/INN)
Fampridine [USAN:INN]
Fampridine SR
Fampridine-PR
Fampridine-SR
Fampridinum
FT-0083754
gamma-Aminopyridine
HC150041
HMS1361O04
HMS1791O04
HMS1921H15
HMS1989O04
HMS2092F05
HMS501M14
HSDB 6037
IDI1_000572
IDI1_034032
|
InChI=1/C5H6N2/c6-5-1-3-7-4-2-5/h1-4H,(H2,6,7
KBio1_000572
KBio2_000282
KBio2_000635
KBio2_002850
KBio2_003203
KBio2_005418
KBio2_005771
KBio3_000563
KBio3_000564
KBio3_001888
KBioGR_000282
KBioGR_001505
KBioSS_000282
KBioSS_000635
Lopac0_000032
Lopac-A-0152
LS-130202
Mi-W-3
MLS000069400
MolPort-000-146-022
NCGC00015009-01
NCGC00015009-03
NCGC00015009-12
NCGC00024890-01
NCGC00024890-02
NCGC00024890-03
NCGC00024890-04
NCGC00024890-05
NCGC00024890-06
NCGC00024890-07
NCGC00024890-08
NCGC00024890-09
NCGC00024890-10
nchem.892-comp4
Neurelan
Neurelan (TN)
NINDS_000572
NSC 15041
NSC15041
p-Aminopyridine
p-Aminopyridine [UN2671] [Poison]
p-Aminopyridine [UN2671] [Poison]
Philips 1861
Phillips 1861
Pimadin (free base)
Prc 1237
Pymadin
Pymadine
pyridin-4-amine
pyridin-4-ylamine
PYRIDINE,4-AMINO
RCRA waste no. P008
SDCCGMLS-0066228.P001
SMR000058211
SPBio_001486
Spectrum_000155
SPECTRUM1501130
Spectrum2_001413
Spectrum3_000914
Spectrum4_001013
Spectrum5_001501
STK298717
Sustained Release, 4-Aminopyridine
TL8003344
Tocris-0940
UNII-BH3B64OKL9
UPCMLD-DP125
UPCMLD-DP125:001
VMI 103
VMI 10-3
VMI103
VMI-103
VMI-10-3
WLN: T6NJ DZ
γ-Aminopyridine
|
|
| 21 |
|
Potassium Channel Blockers |
|
Phase 1, Phase 2 |
|
|
|
| 22 |
|
Kava |
Approved, Investigational, Nutraceutical |
|
|
9000-38-8 |
|
Interventional clinical trials:
(show all 14)
| # |
Name |
Status |
NCT ID |
Phase |
Drugs |
| 1 |
Treatment of Pendular Nystagmus With Gabapentin and Memantine in Patients With Oculopalatal Tremor: a Controled Open-label Study |
Completed |
NCT02466191 |
Phase 4 |
Memantine;Gabapentin |
| 2 |
Topical Brinzolamide Ophthalmic Suspension Versus Placebo in the Treatment of Infantile Nystagmus Syndrome |
Completed |
NCT01312402 |
Phase 4 |
topical brinzolamide 1% in 5mL ophthalmic medication;Placebo in 5 mL dispenser |
| 3 |
Phase 2 Study of 4-Aminopyridine for the Treatment of Episodic Ataxia Type 2 |
Unknown status |
NCT01543750 |
Phase 2 |
4-Aminopyridine;Placebo |
| 4 |
Efficacy and Safety of Neramexane Mesylate in Congenital Idiopathic Nystagmus and Acquired Nystagmus: a Randomized, Double-blind, Placebo-controlled, Single Center, Proof of Concept Study Using a Two-period Cross-over Design |
Completed |
NCT00661440 |
Phase 2 |
Neramexane mesylate |
| 5 |
Treatment of Pendular Nystagmus With Gabapentin and Memantine in Patients With Multiple Sclerosis |
Completed |
NCT01744444 |
Phase 2 |
Memantine;Gabapentin |
| 6 |
Horizontal Rectus Tenotomy in the Treatment of Congenital Nystagmus |
Completed |
NCT00001866 |
Phase 2 |
|
| 7 |
A Single Dose Pharmaco-Diagnostic for Peripheral Nerve Continuity After Trauma |
Not yet recruiting |
NCT04026568 |
Phase 1, Phase 2 |
4-Aminopyridine;Placebo oral tablet |
| 8 |
Long-term Open-label Extension Study to Assess the Safety, Tolerability, and Efficacy of Neramexane Mesylate in Congenital Idiopathic Nystagmus and Acquired Nystagmus |
Terminated |
NCT00799942 |
Phase 2 |
Neramexane mesylate |
| 9 |
Effects of Vestibular Rehabilitation in the Treatment of Patients With Acute Vestibular Loss. - A Randomized Controlled Trial |
Completed |
NCT00702832 |
|
|
| 10 |
Investigation and Treatment of Ocular Motor Disorders: Cross-over Comparison of Gabapentin and Memantine as Treatment for Nystagmus |
Completed |
NCT00928954 |
|
gabapentin;memantine |
| 11 |
Screening Study for the Evaluation and Diagnosis of Potential Research Subjects With Nystagmus or Strabismus |
Completed |
NCT00001861 |
|
|
| 12 |
Production of a Device to Obtain Continuous Ambulatory Vestibular Assessment (CAVA) - Healthy Volunteer Trial |
Completed |
NCT03661762 |
|
|
| 13 |
Coordination of Rare Diseases at Sanford |
Recruiting |
NCT01793168 |
|
|
| 14 |
Biofeedback in Idiopathic Infantile Nystagmus Syndrome |
Recruiting |
NCT04142307 |
|
|
|
